Phentermine/Topiramate ER Dosing and Management for Patients on 15 mg Phentermine

Recommended Fixed‑Dose Combination

• The appropriate regimen for a patient already receiving 15 mg phentermine is the fixed‑dose combination phentermine/topiramate ER 15 mg/92 mg taken once daily. [1][2]3

Titration Schedule (U.S. FDA‑approved protocol)

• Weeks 1‑2: Begin with phentermine/topiramate ER 3.75 mg/23 mg once daily in the morning. [1][4]5
• Weeks 3‑12: Increase to 7.5 mg/46 mg once daily; this is the recommended maintenance dose. [2][4]
• Week 12 assessment: If weight loss is < 3 % of baseline, consider dose escalation. [2][5]
• Weeks 12‑14 (if escalating): Use 11.25 mg/69 mg once daily for 14 days. [4][5]
• Week 14 onward: Maximum approved dose is 15 mg/92 mg once daily. [1][2]4

Decision Points at 12 Weeks

• On 7.5 mg/46 mg:

  • If weight loss < 3 %, either discontinue therapy or escalate to the maximum dose. 5
  • If the response is adequate, continue the current dose. 4

• On 15 mg/92 mg:

  • If weight loss < 5 %, discontinue the medication. 5
  • Discontinuation must be tapered (e.g., every other day for ≥ 1 week) to avoid seizure risk. [1][6]

Efficacy by Dose (Weight‑Loss Outcomes)

*Percent change from baseline. [1][2][3][6]7

Safety – Contraindications (U.S. FDA)

• Pregnancy (topiramate is teratogenic and increases risk of orofacial clefts). [2][4]
• Uncontrolled hypertension or other cardiovascular disease. [1][8]
• Acute angle‑closure glaucoma. [1][8]
• Hyperthyroidism. [1][8]
• Use of monoamine‑oxidase inhibitors within the preceding 14 days. [1][4]

Safety – Required Monitoring

• Pregnancy testing: Serum β‑hCG before starting therapy and monthly home testing thereafter. 1
• Electrolytes & creatinine: Baseline and periodic checks (topiramate can cause metabolic acidosis and hypokalemia). [1][8]
• Heart rate & blood pressure: Monitor because phentermine can raise both parameters. [1][9]
• Mood & depression screening: Assess for worsening depression or suicidal ideation. [1][8]

Common Pitfalls

• Prescribing the components separately is unsafe; only the FDA‑approved extended‑release fixed‑dose combination should be used. 2
• Skipping titration steps markedly increases the risk of paresthesias, cognitive impairment, and mood changes. [1][2]
• Abrupt discontinuation of the 15 mg/92 mg dose can precipitate seizures; a taper is mandatory. [1][6]

Drug‑Interaction Alerts

• Oral contraceptives: May cause breakthrough bleeding due to altered estrogen/progestin metabolism. 1
• Diuretics (e.g., hydrochlorothiazide, furosemide): Heighten the risk of hypokalemia. [1][8]
• Other antiepileptics: Topiramate can modify their plasma concentrations. 1

Side‑Effect Management

• Paresthesias: Most common, usually transient and dose‑related; may resolve with dose reduction. [1][2]
• Cognitive effects (e.g., word‑finding difficulty, drowsiness): Consider lowering the dose if problematic. [1][9]
• Metabolic acidosis: Check serum bicarbonate when symptoms arise. [1][8]
• Nephrolithiasis: Encourage adequate hydration to mitigate stone formation. [1][8]

Renal Impairment Adjustments (Fixed‑Dose Combination)

• In moderate‑to‑severe renal impairment, the phentermine/topiramate ER dose must be reduced; the exact adjustment follows FDA guidance for the combination product. [1][9]